EA200600200A1 - Способ лечения синдрома отвыкания от зависимости - Google Patents
Способ лечения синдрома отвыкания от зависимостиInfo
- Publication number
- EA200600200A1 EA200600200A1 EA200600200A EA200600200A EA200600200A1 EA 200600200 A1 EA200600200 A1 EA 200600200A1 EA 200600200 A EA200600200 A EA 200600200A EA 200600200 A EA200600200 A EA 200600200A EA 200600200 A1 EA200600200 A1 EA 200600200A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- buprenorphine
- dosage form
- dosage
- syndrome
- days
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Materials Engineering (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Cephalosporin Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Drying Of Semiconductors (AREA)
Abstract
Описаны схемы приема бупренорфина для лечения синдрома отвыкания от зависимости или обстиненции у пациентки, зависимой от лекарства или привыкшей к опиоиду, которая является беременной. Способ включает лечение синдрома отвыкания от зависимости или абстиненции путем трансдермального введения количества бупренорфина, эффективного для ослабления симптомов синдрома отвыкания. Например, первая, содержащая бупренорфин трансдермальная дозированная форма может вводиться в течение первого периода дозирования, составляющего не более примерно 5 дней, вторая, содержащая бупренорфин трансдермальная дозированная форма - в течение второго периода дозирования, который составляет не более примерно 5 дней, при этом вторая дозированная форма содержит ту же дозу или большую дозу, чем первая дозированная форма, и третья содержащая бупренорфин трансдермальная дозированная форма вводится в течение третьего периода дозирования, составляющего по меньшей мере 2 дня, при этом третья дозированная форма содержит ту же или большую дозу бупренорфина, что и вторая дозированная форма.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49040703P | 2003-07-25 | 2003-07-25 | |
| PCT/US2004/024010 WO2005011579A2 (en) | 2003-07-25 | 2004-07-26 | Treatment of dependence withdrawal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600200A1 true EA200600200A1 (ru) | 2006-06-30 |
| EA009921B1 EA009921B1 (ru) | 2008-04-28 |
Family
ID=34115390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600200A EA009921B1 (ru) | 2003-07-25 | 2004-07-26 | Способ лечения синдрома отвыкания от зависимости у беременных женщин |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8637073B2 (ru) |
| EP (1) | EP1646328B1 (ru) |
| JP (2) | JP2007500134A (ru) |
| KR (1) | KR100829492B1 (ru) |
| CN (1) | CN1829482B (ru) |
| AT (1) | ATE375149T1 (ru) |
| AU (1) | AU2004261182B2 (ru) |
| BR (1) | BRPI0412931A (ru) |
| CA (1) | CA2530005C (ru) |
| CY (1) | CY1107262T1 (ru) |
| DE (1) | DE602004009449T2 (ru) |
| DK (1) | DK1646328T3 (ru) |
| EA (1) | EA009921B1 (ru) |
| ES (1) | ES2295929T3 (ru) |
| GE (1) | GEP20125454B (ru) |
| HR (1) | HRP20070476T3 (ru) |
| IL (1) | IL173346A (ru) |
| IS (1) | IS2630B (ru) |
| MA (1) | MA28004A1 (ru) |
| MX (1) | MXPA06000991A (ru) |
| NO (1) | NO333189B1 (ru) |
| NZ (1) | NZ545505A (ru) |
| PL (1) | PL1646328T3 (ru) |
| PT (1) | PT1646328E (ru) |
| SI (1) | SI1646328T1 (ru) |
| UA (1) | UA81056C2 (ru) |
| WO (1) | WO2005011579A2 (ru) |
| ZA (1) | ZA200510069B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| MXPA05006334A (es) * | 2002-12-13 | 2005-08-26 | Euro Celtique Sa | Dosis de buprenorfina transdermica para analgesia. |
| EP1913938A1 (en) * | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| UA81056C2 (en) | 2003-07-25 | 2007-11-26 | Euro Celtic S A | Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine |
| CA2622684A1 (en) * | 2005-09-30 | 2007-04-12 | Darrick Carter | Transdermal drug delivery systems, devices, and methods employing opioid agonist and/or opioid antagonist |
| JP2011513287A (ja) * | 2008-02-28 | 2011-04-28 | シントロファーマ リミテッド | 医薬品組成物 |
| US8163731B2 (en) * | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| US9879204B2 (en) | 2010-03-17 | 2018-01-30 | Method Products, Pbc | Liquid cleaning compositions with lower freezing point |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | Dow Agrosciences Llc | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| HK1206978A1 (en) | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| DK3400066T3 (da) * | 2016-01-08 | 2021-10-18 | Ohio State Innovation Foundation | Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom |
| CA3068036A1 (en) | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | Use to buprenorphine in combination with an opioid to treat pain |
| CN107648234A (zh) * | 2017-08-04 | 2018-02-02 | 中国人民解放军第二军医大学 | 一种治疗吗啡成瘾戒断症状的阿片类药物组合物 |
| WO2019199704A1 (en) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
| WO2021043771A1 (en) * | 2019-09-02 | 2021-03-11 | Camurus Ab | Formulations and treatment methods |
| AU2022213437A1 (en) * | 2021-02-01 | 2023-08-17 | Clear Scientific, Inc. | Sequestration compounds for treatment of substance use disorder and uses thereof |
| EP4568672A2 (en) * | 2022-08-12 | 2025-06-18 | Bioventures, Llc | Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058599A (en) | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
| DE3939376C1 (ru) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| EP0432945A1 (en) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | A transdermal delivery system for treatment of cocaine and heroin addiction |
| US5272149A (en) | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH06183956A (ja) * | 1992-12-24 | 1994-07-05 | Teisan Seiyaku Kk | 安定な貼付用の製剤 |
| JP2819236B2 (ja) | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| KR100383252B1 (ko) | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
| WO2003037313A2 (en) | 2001-10-31 | 2003-05-08 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| US20030181475A1 (en) | 2002-03-20 | 2003-09-25 | Euro-Celtique S.A. | Method of administering buprenorphine to treat depression |
| MXPA05006334A (es) | 2002-12-13 | 2005-08-26 | Euro Celtique Sa | Dosis de buprenorfina transdermica para analgesia. |
| WO2004103317A2 (en) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
| UA81056C2 (en) | 2003-07-25 | 2007-11-26 | Euro Celtic S A | Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine |
-
2004
- 2004-07-26 UA UAA200602136A patent/UA81056C2/uk unknown
- 2004-07-26 CN CN2004800215633A patent/CN1829482B/zh not_active Expired - Fee Related
- 2004-07-26 GE GEAP20049184A patent/GEP20125454B/en unknown
- 2004-07-26 US US10/566,121 patent/US8637073B2/en active Active
- 2004-07-26 PL PL04779186T patent/PL1646328T3/pl unknown
- 2004-07-26 AT AT04779186T patent/ATE375149T1/de active
- 2004-07-26 SI SI200430545T patent/SI1646328T1/sl unknown
- 2004-07-26 HR HR20070476T patent/HRP20070476T3/xx unknown
- 2004-07-26 KR KR1020067001688A patent/KR100829492B1/ko not_active Expired - Fee Related
- 2004-07-26 EA EA200600200A patent/EA009921B1/ru not_active IP Right Cessation
- 2004-07-26 MX MXPA06000991A patent/MXPA06000991A/es active IP Right Grant
- 2004-07-26 DE DE602004009449T patent/DE602004009449T2/de not_active Expired - Lifetime
- 2004-07-26 ES ES04779186T patent/ES2295929T3/es not_active Expired - Lifetime
- 2004-07-26 CA CA2530005A patent/CA2530005C/en not_active Expired - Fee Related
- 2004-07-26 NZ NZ545505A patent/NZ545505A/en not_active IP Right Cessation
- 2004-07-26 AU AU2004261182A patent/AU2004261182B2/en not_active Ceased
- 2004-07-26 BR BRPI0412931-8A patent/BRPI0412931A/pt not_active Application Discontinuation
- 2004-07-26 WO PCT/US2004/024010 patent/WO2005011579A2/en not_active Ceased
- 2004-07-26 EP EP04779186A patent/EP1646328B1/en not_active Expired - Lifetime
- 2004-07-26 JP JP2006521307A patent/JP2007500134A/ja active Pending
- 2004-07-26 PT PT04779186T patent/PT1646328E/pt unknown
- 2004-07-26 DK DK04779186T patent/DK1646328T3/da active
-
2005
- 2005-12-12 ZA ZA200510069A patent/ZA200510069B/en unknown
- 2005-12-19 IS IS8187A patent/IS2630B/is unknown
-
2006
- 2006-01-24 IL IL173346A patent/IL173346A/en not_active IP Right Cessation
- 2006-02-23 MA MA28830A patent/MA28004A1/fr unknown
- 2006-02-24 NO NO20060913A patent/NO333189B1/no not_active IP Right Cessation
-
2008
- 2008-01-08 CY CY20081100020T patent/CY1107262T1/el unknown
-
2011
- 2011-08-18 JP JP2011179129A patent/JP2011252020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| DE60326354D1 (de) | Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form | |
| DK1476141T3 (da) | Manipulationssikrede anordninger til transdermal opioidadministration | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| NO20014842D0 (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
| DK1572167T3 (da) | Transdermal buprenophindoseringsbehandlingsplan for analgesi | |
| JP2002523370A5 (ru) | ||
| JP2004537500A5 (ru) | ||
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| BR0307022A (pt) | Método de tratamento de um paciente que precisa de analgesia | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| Naber et al. | Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG RU |